Duration of psychosis and outcome in first-episode schizophrenia
OBJECTIVE: This study was undertaken to assess the potential effect of duration of untreated illness on outcome in a group of first-episode schizophrenic patients. METHOD: Seventy patients with schizophrenia diagnosed according to the Research Diagnostic Criteria entered the study and were followed...
Gespeichert in:
Veröffentlicht in: | The American journal of psychiatry 1992-09, Vol.149 (9), p.1183-1188 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1188 |
---|---|
container_issue | 9 |
container_start_page | 1183 |
container_title | The American journal of psychiatry |
container_volume | 149 |
creator | LOEBEL, A. D LIEBERMAN, J. A ALVIR, J. M. J AYERHOFF, D. I GEISLER, S. H SZYMANSKI, S. R |
description | OBJECTIVE: This study was undertaken to assess the potential effect of
duration of untreated illness on outcome in a group of first-episode
schizophrenic patients. METHOD: Seventy patients with schizophrenia
diagnosed according to the Research Diagnostic Criteria entered the study
and were followed for up to 3 years. All patients received standardized
treatment and uniform assessments both during the acute phase of their
illness and throughout the follow-up period. Outcome was measured in terms
of time to remission of acute psychotic symptoms as well as degree of
symptom remission. RESULTS: The mean duration of psychotic symptoms before
initial treatment was 52 weeks, preceded by a substantial prepsychotic
period. According to survival analysis, duration of illness before
treatment was found to be significantly associated with time to remission
as well as with level of remission. The effect of duration of illness on
outcome remained significant when diagnosis and gender variables,
themselves associated with outcome, were controlled in a regression
analysis. Duration of illness was not correlated with age at onset, mode of
onset, premorbid adjustment, or severity of illness at entry into the
study. CONCLUSIONS: Duration of psychosis before treatment may be an
important predictor of outcome in first-episode schizophrenia. Acute
psychotic symptoms could reflect an active morbid process which, if not
ameliorated by neuroleptic drug treatment, may result in lasting morbidity.
Further implications of these findings are discussed. |
doi_str_mv | 10.1176/ajp.149.9.1183 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73130714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1310600801</sourcerecordid><originalsourceid>FETCH-LOGICAL-a476t-ca7e0330d2ae457ff0478440878502ad4bb028f620720387f9b78dc735fc1a5e3</originalsourceid><addsrcrecordid>eNp10E1r3DAQBmARGtLNxzW3gmlLLsHu6MuSby1JmgYCuaSQm5BlidViW65kH5JfXy27JKW0JzHMo9HoRegcQ4WxqL_ozVRh1lRNLiU9QCvMKS8FIfIdWgEAKRtOn96j45Q2uQQqyBE6whwoprBCX6-XqGcfxiK4YkrPZh2ST4UeuyIsswmDLfxYOB_TXNrJp9DZIpm1fwnTOtrR61N06HSf7Nn-PEE_v988Xv0o7x9u766-3ZeaiXoujRYWKIWOaMu4cA6YkIyBFJID0R1rWyDS1QQEASqFa1ohOyModwZrbukJutjNnWL4tdg0q8EnY_tejzYsSYntfwRmGX78C27CEse8myIEmJS4lhl9-h_CFEMNIAFnVe2UiSGlaJ2aoh90fFYY1DZ9ldNXOX3VqG36-cKH_dilHWz3xndx5_7nfV8no3sX9Wh8emWc1Rxzntnljulp8n9s9u9HfwOp55hS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310600801</pqid></control><display><type>article</type><title>Duration of psychosis and outcome in first-episode schizophrenia</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>LOEBEL, A. D ; LIEBERMAN, J. A ; ALVIR, J. M. J ; AYERHOFF, D. I ; GEISLER, S. H ; SZYMANSKI, S. R</creator><creatorcontrib>LOEBEL, A. D ; LIEBERMAN, J. A ; ALVIR, J. M. J ; AYERHOFF, D. I ; GEISLER, S. H ; SZYMANSKI, S. R</creatorcontrib><description>OBJECTIVE: This study was undertaken to assess the potential effect of
duration of untreated illness on outcome in a group of first-episode
schizophrenic patients. METHOD: Seventy patients with schizophrenia
diagnosed according to the Research Diagnostic Criteria entered the study
and were followed for up to 3 years. All patients received standardized
treatment and uniform assessments both during the acute phase of their
illness and throughout the follow-up period. Outcome was measured in terms
of time to remission of acute psychotic symptoms as well as degree of
symptom remission. RESULTS: The mean duration of psychotic symptoms before
initial treatment was 52 weeks, preceded by a substantial prepsychotic
period. According to survival analysis, duration of illness before
treatment was found to be significantly associated with time to remission
as well as with level of remission. The effect of duration of illness on
outcome remained significant when diagnosis and gender variables,
themselves associated with outcome, were controlled in a regression
analysis. Duration of illness was not correlated with age at onset, mode of
onset, premorbid adjustment, or severity of illness at entry into the
study. CONCLUSIONS: Duration of psychosis before treatment may be an
important predictor of outcome in first-episode schizophrenia. Acute
psychotic symptoms could reflect an active morbid process which, if not
ameliorated by neuroleptic drug treatment, may result in lasting morbidity.
Further implications of these findings are discussed.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.149.9.1183</identifier><identifier>PMID: 1503130</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Adult and adolescent clinical studies ; Biological and medical sciences ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Psychiatric Status Rating Scales ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Psychosis ; Psychotic Disorders - diagnosis ; Psychotic Disorders - drug therapy ; Psychotic Disorders - psychology ; Psychotropic Drugs - therapeutic use ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Severity of Illness Index ; Social research ; Survival Analysis ; Time Factors ; Treatment Outcome</subject><ispartof>The American journal of psychiatry, 1992-09, Vol.149 (9), p.1183-1188</ispartof><rights>1992 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Sep 1992</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a476t-ca7e0330d2ae457ff0478440878502ad4bb028f620720387f9b78dc735fc1a5e3</citedby><cites>FETCH-LOGICAL-a476t-ca7e0330d2ae457ff0478440878502ad4bb028f620720387f9b78dc735fc1a5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.149.9.1183$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.149.9.1183$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2859,21629,27869,27924,27925,77791,77792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5465155$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1503130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LOEBEL, A. D</creatorcontrib><creatorcontrib>LIEBERMAN, J. A</creatorcontrib><creatorcontrib>ALVIR, J. M. J</creatorcontrib><creatorcontrib>AYERHOFF, D. I</creatorcontrib><creatorcontrib>GEISLER, S. H</creatorcontrib><creatorcontrib>SZYMANSKI, S. R</creatorcontrib><title>Duration of psychosis and outcome in first-episode schizophrenia</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: This study was undertaken to assess the potential effect of
duration of untreated illness on outcome in a group of first-episode
schizophrenic patients. METHOD: Seventy patients with schizophrenia
diagnosed according to the Research Diagnostic Criteria entered the study
and were followed for up to 3 years. All patients received standardized
treatment and uniform assessments both during the acute phase of their
illness and throughout the follow-up period. Outcome was measured in terms
of time to remission of acute psychotic symptoms as well as degree of
symptom remission. RESULTS: The mean duration of psychotic symptoms before
initial treatment was 52 weeks, preceded by a substantial prepsychotic
period. According to survival analysis, duration of illness before
treatment was found to be significantly associated with time to remission
as well as with level of remission. The effect of duration of illness on
outcome remained significant when diagnosis and gender variables,
themselves associated with outcome, were controlled in a regression
analysis. Duration of illness was not correlated with age at onset, mode of
onset, premorbid adjustment, or severity of illness at entry into the
study. CONCLUSIONS: Duration of psychosis before treatment may be an
important predictor of outcome in first-episode schizophrenia. Acute
psychotic symptoms could reflect an active morbid process which, if not
ameliorated by neuroleptic drug treatment, may result in lasting morbidity.
Further implications of these findings are discussed.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Psychosis</subject><subject>Psychotic Disorders - diagnosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - psychology</subject><subject>Psychotropic Drugs - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Severity of Illness Index</subject><subject>Social research</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp10E1r3DAQBmARGtLNxzW3gmlLLsHu6MuSby1JmgYCuaSQm5BlidViW65kH5JfXy27JKW0JzHMo9HoRegcQ4WxqL_ozVRh1lRNLiU9QCvMKS8FIfIdWgEAKRtOn96j45Q2uQQqyBE6whwoprBCX6-XqGcfxiK4YkrPZh2ST4UeuyIsswmDLfxYOB_TXNrJp9DZIpm1fwnTOtrR61N06HSf7Nn-PEE_v988Xv0o7x9u766-3ZeaiXoujRYWKIWOaMu4cA6YkIyBFJID0R1rWyDS1QQEASqFa1ohOyModwZrbukJutjNnWL4tdg0q8EnY_tejzYsSYntfwRmGX78C27CEse8myIEmJS4lhl9-h_CFEMNIAFnVe2UiSGlaJ2aoh90fFYY1DZ9ldNXOX3VqG36-cKH_dilHWz3xndx5_7nfV8no3sX9Wh8emWc1Rxzntnljulp8n9s9u9HfwOp55hS</recordid><startdate>19920901</startdate><enddate>19920901</enddate><creator>LOEBEL, A. D</creator><creator>LIEBERMAN, J. A</creator><creator>ALVIR, J. M. J</creator><creator>AYERHOFF, D. I</creator><creator>GEISLER, S. H</creator><creator>SZYMANSKI, S. R</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19920901</creationdate><title>Duration of psychosis and outcome in first-episode schizophrenia</title><author>LOEBEL, A. D ; LIEBERMAN, J. A ; ALVIR, J. M. J ; AYERHOFF, D. I ; GEISLER, S. H ; SZYMANSKI, S. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a476t-ca7e0330d2ae457ff0478440878502ad4bb028f620720387f9b78dc735fc1a5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Psychosis</topic><topic>Psychotic Disorders - diagnosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - psychology</topic><topic>Psychotropic Drugs - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Severity of Illness Index</topic><topic>Social research</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LOEBEL, A. D</creatorcontrib><creatorcontrib>LIEBERMAN, J. A</creatorcontrib><creatorcontrib>ALVIR, J. M. J</creatorcontrib><creatorcontrib>AYERHOFF, D. I</creatorcontrib><creatorcontrib>GEISLER, S. H</creatorcontrib><creatorcontrib>SZYMANSKI, S. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LOEBEL, A. D</au><au>LIEBERMAN, J. A</au><au>ALVIR, J. M. J</au><au>AYERHOFF, D. I</au><au>GEISLER, S. H</au><au>SZYMANSKI, S. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duration of psychosis and outcome in first-episode schizophrenia</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1992-09-01</date><risdate>1992</risdate><volume>149</volume><issue>9</issue><spage>1183</spage><epage>1188</epage><pages>1183-1188</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: This study was undertaken to assess the potential effect of
duration of untreated illness on outcome in a group of first-episode
schizophrenic patients. METHOD: Seventy patients with schizophrenia
diagnosed according to the Research Diagnostic Criteria entered the study
and were followed for up to 3 years. All patients received standardized
treatment and uniform assessments both during the acute phase of their
illness and throughout the follow-up period. Outcome was measured in terms
of time to remission of acute psychotic symptoms as well as degree of
symptom remission. RESULTS: The mean duration of psychotic symptoms before
initial treatment was 52 weeks, preceded by a substantial prepsychotic
period. According to survival analysis, duration of illness before
treatment was found to be significantly associated with time to remission
as well as with level of remission. The effect of duration of illness on
outcome remained significant when diagnosis and gender variables,
themselves associated with outcome, were controlled in a regression
analysis. Duration of illness was not correlated with age at onset, mode of
onset, premorbid adjustment, or severity of illness at entry into the
study. CONCLUSIONS: Duration of psychosis before treatment may be an
important predictor of outcome in first-episode schizophrenia. Acute
psychotic symptoms could reflect an active morbid process which, if not
ameliorated by neuroleptic drug treatment, may result in lasting morbidity.
Further implications of these findings are discussed.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>1503130</pmid><doi>10.1176/ajp.149.9.1183</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 1992-09, Vol.149 (9), p.1183-1188 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_73130714 |
source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
subjects | Adult Adult and adolescent clinical studies Biological and medical sciences Female Follow-Up Studies Humans Male Medical sciences Psychiatric Status Rating Scales Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Psychosis Psychotic Disorders - diagnosis Psychotic Disorders - drug therapy Psychotic Disorders - psychology Psychotropic Drugs - therapeutic use Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Severity of Illness Index Social research Survival Analysis Time Factors Treatment Outcome |
title | Duration of psychosis and outcome in first-episode schizophrenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duration%20of%20psychosis%20and%20outcome%20in%20first-episode%20schizophrenia&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=LOEBEL,%20A.%20D&rft.date=1992-09-01&rft.volume=149&rft.issue=9&rft.spage=1183&rft.epage=1188&rft.pages=1183-1188&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.149.9.1183&rft_dat=%3Cproquest_cross%3E1310600801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310600801&rft_id=info:pmid/1503130&rfr_iscdi=true |